Portal de Periódicos da CAPES

First clinical comparison of Nobori –Biolimus A9 eluting stents with Cypher– Sirolimus eluting stents: Nobori Core nine months angiographic and one year clinical outcomes

2008; European Association of Percutaneous Cardiovascular Interventions; Volume: 3; Issue: 5 Linguagem: Inglês

10.4244/eijv3i5a103

1969-6213

Miodrag Ostojić, Dragan Sagić, Branko Beleslin, Robert Jung, Zoran Perišić, Nikola Jagić, Milan Nedeljković, Ljupco Mangovski, Bratislav Milosavljevic, Siniša Stojković, Dejan Orlić, Želimir Antonić, Vladimir Miloradović, Dragan Topic, Dragica Paunovic,

Cardiac Valve Diseases and Treatments

To compare clinical efficacy and safety of stents eluting limus drugs from biodegradable polymer - Nobori, or durable polymer - Cypher.From May to August 2006, 107 patients with 142 coronary artery lesions were treated with either Nobori, Biolimus A9 eluting stent (54) or Cypher, Sirolimus eluting stent (53) in five centres. The two groups were well matched for baseline clinical and angiographic characteristics. The in-stent late loss at nine months, the primary endpoint of the study, was 0.10+/-0.26 mm in Nobori, and 0.13+/-0.44 mm in Cypher arm (p=0.660) confirming the hypothesis of the similarity between the two stents. In-stent diameter stenosis of 13+/-10% with Nobori was significantly lower than 20+/-12% with Cypher stent (p=0.002) without significant difference in binary restenosis (1.7% in Nobori and 6.3% in Cypher arm; p=0.32). The rate of major adverse cardiac events at 12 months was 1.9% with Nobori and 4.1% with Cypher stent.The nine months angiographic data from Nobori Core study demonstrate that Biolimus A9 has similar anti-proliferative efficacy to Sirolimus as judged by in-stent late loss and restenosis rate. Low frequency of adverse cardiac events at 12 months indicates that both stents are safe and effective in the studied population.